Suppression of cancer relapse and metastasis by inhibiting cancer stemness

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 6, 2015, Pages 1839-1844

  Li, Youzhi ^a   Rogoff, Harry A ^a   Keates, Sarah ^a   Gao, Yuan ^a   Murikipudi, Sylaja ^a   Mikule, Keith ^a   Leggett, David ^a   Li, Wei ^a   Pardee, Arthur B ^a   Li, Chiang J ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

BBI608; Cancer stemness; Relapse

Indexed keywords

BETA CATENIN; BMI1 PROTEIN; CARBOPLATIN; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; NAPABUCASIN; REGORAFENIB; STAT3 PROTEIN; SUNITINIB; SURVIVIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CELL ISOLATION; CELL KILLING; CELL RENEWAL; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LIVER METASTASIS; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SPLEEN METASTASIS; TUMOR XENOGRAFT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; NEOPLASM METASTASIS; PROCEDURES; SECONDARY PREVENTION; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROGRAFTS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; SECONDARY PREVENTION;

EID: 84922611324     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424171112     Document Type: Article

References (46)

1. Shekhar MP (2011) Drug resistance: Challenges to effective therapy. Curr Cancer Drug Targets 11(5):613-623.
2. Nakata A, Gotoh N (2012) Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets 16(8):771-781.
3. Bucheit AD, Davies MA (2014) Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 87(3):381-389.
4. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328-337.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-3988.
6. Dalerba P, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104(24):10158-10163.
7. Eramo A, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504-514.
8. Kim MP, et al. (2011) ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 6(6):e20636.
9. Li C, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3): 1030-1037.
10. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106-110.
11. Prince ME, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104(3): 973-978.
12. Singh SK, et al. (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396-401.
13. Lapidot T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645-648.
14. Blagosklonny MV (2007) Cancer stem cell and cancer stemloids: From biology to therapy. Cancer Biol Ther 6(11):1684-1690.
15. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755-768.
16. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105-111.
17. Chen SF, et al. (2012) Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS ONE 7(2):e31864.
18. Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ (2012) Ionizing radiation induces stemness in cancer cells. PLoS ONE 7(8):e43628.
19. Hu X, et al. (2012) Induction of cancer cell stemness by chemotherapy. Cell Cycle 11(14):2691-2698.
20. Milas L, Hittelman WN (2009) Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol 19(2):96-105.
21. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP (2012) The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol 13(2):e83-e89.
22. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167-1174.
23. Jin L, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1): 31-42.
24. Kikushige Y, et al. (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6):708-717.
25. Wong DJ, et al. (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2(4):333-344.
26. Colak S, Medema JP (2014) Cancer stem cells-important players in tumor therapy resistance. FEBS J 281(21):4779-4791.
27. Garner JM, et al. (2013) Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 288(36):26167-26176.
28. Lee TK, et al. (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9(1):50-63.
29. Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 14(11):736-746.
30. Bromberg J, Darnell JE, Jr (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19(21):2468-2473.
31. Bromberg JF, et al. (1999) Stat3 as an oncogene. Cell 98(3):295-303.
32. Darnell JE, Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740-749.
33. Gupta PB, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633-644.
34. Vermeulen L, et al. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468-476.
35. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275-284.
36. Rizzino A (2013) Concise review: The Sox2-Oct4 connection: Critical players in a much larger interdependent network integrated at multiple levels. Stem Cells 31(6): 1033-1039.
37. Saunders A, Faiola F, Wang J (2013) Concise review: Pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells 31(7):1227-1236.
38. Gujral TS, et al. (2014) A noncanonical frizzled2 pathway regulates epithelialmesenchymal transition and metastasis. Cell 159(4):844-856.
39. Marotta LL, et al. (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest 121(7): 2723-2735.
40. Kato Y, et al. (2005) Selective activation of STAT5 unveils its role in stem cell selfrenewal in normal and leukemic hematopoiesis. J Exp Med 202(1):169-179.
41. Langleben A, et al. (2013) A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. J Clin Oncol 31(15 Suppl): 2542.
42. Dave B, Chang J (2009) Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14(1):79-82.
43. Li S, et al. (2014) Model of tumor dormancy/recurrence after short-term chemotherapy. PLoS ONE 9(5):e98021.
44. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672-679.
45. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13(10):714-726.
46. Wulf GG, et al. (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4):1166-1173.